Detection of circulating tumor cells in patients with non–small cell lung cancer undergoing lobectomy by video-assisted thoracic surgery: A potential hazard for intraoperative hematogenous tumor cell dissemination  by Yamashita, Jun-ichi et al.
T he recent introduction of video-assisted thoracicsurgery (VATS) has allowed many procedures that
previously required a thoracotomy to be performed by
way of this “minimally invasive approach.” Lung biop-
sy, wedge resection of pulmonary nodules, bullectomy,
and resection of mediastinal tumors have now all been
successfully and safely accomplished by a VATS
approach.1-3 Well-accepted advantages of VATS include
decreased postoperative pain, shortened hospital stays,
and a faster return to work.4 Recently, VATS has been
adopted by some thoracic surgeons as the preferred
approach over the standard thoracotomy for the curative
resection of lung cancer because it is associated with
less morbidity. However, the intraoperative hematoge-
Objective: We prospectively tested whether circulating tumor cells can be
found in the preoperative, intraoperative, and postoperative peripheral blood
of patients with resectable non–small cell lung cancer who undergo video-
assisted lobectomy.
Methods: We assayed for carcinoembryonic antigen messenger RNA
(mRNA) by reverse transcriptase–polymerase chain reaction in the peripher-
al blood taken before, during, just after the completion of the lobectomy and
then 2 to 3 weeks, and again 5 to 6 weeks, after the operation in 29 patients
with pathologic stage I non–small cell lung cancer who underwent video-
assisted lobectomy. We also analyzed the prognostic value of carcinoembry-
onic antigen mRNA expression pattern in an additional 57 patients with
stage I non–small cell lung cancer, whose blood samples were previously
assayed for carcinoembryonic antigen mRNA.
Results: Of the 29 patients, the preoperative blood samples from 18 patients
were negative for carcinoembryonic antigen mRNA. Of these 18 patients, 16
(89%) had positive test results during operation, although the remaining 2
patients (11%) consistently showed negative test results. The occurrence of
this change from negative to positive tests results for carcinoembryonic anti-
gen mRNA during video-assisted lobectomy was significantly higher than in
patients who underwent open lobectomy in a previous study (18 of 35
patients; 51%; P < .001). In the 57 patients with stage I cancer whose blood
samples were previously assayed for carcinoembryonic antigen mRNA,
patients with persistently positive test results for carcinoembryonic antigen
mRNA before and during operation had a significantly shorter survival when
compared with those patients whose test results were persistently positive.
Conclusions: Video-assisted lobectomy, as compared with open lobectomy,
for non–small cell lung cancer may increase the risk of seeding tumor cells
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nous dissemination of tumor by this technique is a
potential hazard. One limitation of the VATS technique
is that lung tumors are often not visualized at all or, if
visualized, are detected only as a distortion of the vis-
ceral surface and are palpable only with the fingertips.
Therefore, the surgeon may inadequately identify the
margins of the malignant tumor by VATS, as compared
with the standard thoracotomy operation. In addition,
compared with the open lobectomy procedure, the sur-
geon may need more frequent and stronger traction and
more manipulation of the pulmonary lobes containing
the tumor on all sides by forceps to get a better field of
vision and to ligate the lobar bronchovascular pedicles.
These technical problems of the VATS procedure raise
concerns that VATS techniques may be more likely to
disseminate malignant tumors than the type of manipu-
lation that occurs during an open thoracotomy.
However, in contrast to the many claims of benefits
from the VATS procedure, there have been few studies
to address this issue.
Although the presence of circulating tumor cells does
not necessarily predict the subsequent appearance of
clinical systemic disease, such tumor cells have the
potential to establish metastases and so may have a
negative influence on patient prognosis. Because the
number of circulating cells may be very small, methods
for their detection must be both sensitive and specific.
Morphologic features, flow cytometry, conventional
cytogenetics, and immunocytochemistry have been
used to detect circulating tumor cells. However, these
techniques are relatively insensitive, and some depend
on the interaction of antibodies with tumor-associated
cell-surface antigens.5,6 Recent developments in molec-
ular technology, including the advent of the polymerase
chain reaction (PCR), have permitted the sensitive
detection of circulating tumor cells in the peripheral
blood.5,7 We and others8-11 have used the carcinoem-
bryonic antigen (CEA) as the target gene because CEA
messenger RNA can be detected in almost all epithelial
cells, including cancer cells, but not in nonepithelial
cells. If CEA mRNA is detected in blood samples, this
implies the presence of ectopic epithelial cells and pre-
sumably cancer cells. The reverse PCR (RT-PCR)
amplification method for CEA mRNA is an efficient
means of detecting cancer cells in peripheral blood
with a high sensitivity. This technique can detect 10
malignant cells in up to 107 normal cells.12 The tech-
nique is also highly specific because no control blood
samples from healthy volunteers were positive for CEA
mRNA.12
In this study, we have detected, by means of an RT-
PCR assay before, during, and after operation, the pres-
ence of CEA mRNA in the peripheral blood of patients
with resectable non–small cell lung cancer (NSCLC)
who underwent VATS lobectomy. In addition, to exam-
ine whether CEA mRNA expression pattern in the
peripheral blood during the procedure is associated
with the prognosis of patients with NSCLC, we per-
formed a survival analysis for an additional 57 patients
with resectable NSCLC who underwent a curative
lobectomy with a standard open thoracotomy and
whose blood samples were previously assayed for CEA
mRNA.11 Because insufficient time has elapsed to ana-
lyze the prognosis in patients in the present study, we
were unable to determine the prognostic significance of
CEA mRNA detection in patients who underwent
resection by VATS.
Patients and methods
Patients. During the 24-month period starting in July
1997, 36 patients with confirmed or what, before the opera-
tion, was thought to be stage IA (T1 N0 M0) or stage IB (T2
N0 M0) NSCLC were entered into this study after informed
consent had been obtained in accordance with the ethics com-
mittees of our institutions. During the same period, 68
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Table I. Summary of CEA mRNA expression patterns in pre-, intra-, and postoperative peripheral blood samples
from 32 patients with NSCLC who underwent VATS lobectomy in terms of pathologic TNM stage
RT-PCR for CEA mRNA Pathologic TNM stage
I II III IV V VI IA IB IIA IIIA Total Clinical outcome
Initially positive group (n = 13) + + + + + + 4 1 0 2 7 Two patients with stage IIIA 
died of recurrence
+ + – – – – 3 0 0 0 3 All patients alive, disease-free 
+ – – – – – 3 0 0 0 3 All patients alive, disease-free 
Initially negative group (n = 19) – – – – – – 2 0 1 0 3 All patients alive, disease-free 
– + + – – – 11 1 0 0 12 All patients alive, disease-free 
– + + – + + 1 0 0 0 1 All patients alive, disease-free 
– + + – – + 2 1 0 0 3 All patients alive, disease-free 
Total 26 3 1 2 32
patients with stage I NSCLC underwent open lobectomy on
patient request. The 2 populations of patients resemble each
other with respect to age, sex, smoking history, histologic
type, and pathologic TNM classification. Two of the 36
patients in this study proved to have nonmalignant disease at
the time of operation and were therefore excluded from the
study. Two additional patients required conversion to a stan-
dard posterolateral open thoracotomy because there was
some difficulty in safely dissecting the interlobar pulmonary
artery or because of incomplete fissures; these patients were
therefore also excluded from the study. This left 32 patients
with NSCLC who underwent VATS lobectomy (Table I). Of
these 32 patients, 1 had postoperative pathologic N1 disease
and 2 had postoperative pathologic N2 disease. Con-
sequently, this study includes 26 patients with stage IA (T1
N0), 3 patients with stage IB (T2 N0), 1 patient with stage
IIA (T1 N1), and 2 patients with stage IIIA (T1 N2 and T2
N2), according to the newly revised classification of the
American Joint Committee on Cancer and the Union
Internationale Contre le Cancer.13 There were 10 men and 22
women, with an age range of 37 to 83 years (mean, 63 years).
The histologic distribution of the resected tumor specimens
was 29 adenocarcinomas, 2 squamous cell carcinomas, and 1
carcinoid, based on the World Health Organization Histologic
Typing of Lung Tumors.14 The median follow-up period was
12 months (range, 1-24 months).
All surgical procedures were performed after the patient
had been given a general anesthetic and with the use of sin-
gle-lung ventilation through a double-lumen endotracheal
tube (Broncho-Cath; Mallinckrodt Medical Inc, St Louis,
Mo). Patients were placed in the lateral decubitus position
with arms extended on an arm rest. VATS lobectomy was per-
formed by techniques previously described, which included a
6- to 8-cm access thoracotomy, through which standard tho-
racic instruments were introduced without rib spreading.15,16
The operations performed for the 32 patients with NSCLC
were right upper lobectomy in 11, right middle lobectomy in
1, right lower lobectomy in 8, left upper lobectomy in 6, and
left lower lobectomy in 6. Pulmonary vessel mobilization and
ligation and hilar and mediastinal lymph node dissection
were performed in a manner similar to those used in the con-
ventional thoracotomy approach. All the surgical procedures
were uniformly and successfully performed by the same 2
authors (J.Y. and N.F.). All the patients had uneventful post-
operative recoveries.
Blood samples. During the operation, a polyethylene
catheter (Becton Dickinson, Sandy, Utah) was inserted into
the radial artery of the contralateral arm (opposite the lobec-
tomy side) for monitoring the heart rate and blood pressure.
Blood samples were taken from this line just before the oper-
ation (point I); 5 minutes after the ligation of the pulmonary
vein or the pulmonary artery (point II); 5 minutes after both
the pulmonary artery and pulmonary vein were ligated (point
III); and 5 minutes after the completion of the lobectomy
(point IV). Blood samples were also taken from the radial
artery after 2 to 3 weeks (point V) and at 5 to 6 weeks (point
VI) after the operation. In case of blood sampling at points V
and VI, the first sampling blood was abandoned to avoid con-
tamination from skin.
RT-PCR for CEA mRNA. The RT-PCR for CEA mRNA
was performed as described previously.11 This RT-PCR assay
could detect CEA mRNA at a cell frequency as low as 10
EBC-1 cells per 107 peripheral blood leukocytes in an in vitro
model.12 In addition, none of the preoperative or postopera-
tive blood samples from 15 patients with interstitial pul-
monary fibrosis who underwent an open-lung biopsy for the
histologic diagnosis nor any of 32 control blood samples
obtained from healthy volunteers were positive for CEA
mRNA by RT-PCR.12
Survival analysis. An important unresolved question is
whether the patients with positive CEA mRNA findings
might have more metastases, shorter survivals, or shorter dis-
ease-free intervals than those who did not have positive find-
ings. However, in this series of patients, insufficient time has
elapsed to perform the survival analysis, and none of the 29
patients with stages IA or IB NSCLC experienced recurrence,
although both patients with stage IIIA died of recurrence
(Table I). Therefore, to determine whether there is a correla-
tion between the CEA mRNA expression pattern in the
peripheral blood samples and prognosis of patients with
NSCLC, we performed disease-free and overall survival
analyses in the previously reported 57 patients. These
patients had pathologic stage I NSCLC (32 patients with
stage IA and 25 patients with stage IB) and underwent a cura-
tive lobectomy by a conventional open thoracotomy proce-
dure,11 accompanied by pre- and intraoperative CEA mRNA
determinations in peripheral blood. Blood samples were not
taken from these patients at the time of 2 to 3 weeks (point V)
or 5 to 6 weeks (point VI) after the operation.
Statistics. Differences in the occurrence of CEA mRNA
expression pattern in the blood samples were calculated by
the χ2 test or the Fisher exact probability test. The disease-
free survival and overall survival curves were generated by
the Kaplan-Meier method.17 The univariate Cox regression
model was used to test for survival differences.
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Table II. Summary of CEA mRNA expression patterns
before and during operation in the peripheral blood
samples from 57 patients with stages IA or IB NSCLC
who underwent open lobectomy
RT-PCR for No. of
CEA mRNA patients %
pattern (% per Per
(I, II, III, IV)* subtotal) total
Initially positive group (n = 22) A (++++) 6 (27) 11
B (++ − −, + − − −) 16 (73) 28
Initially negative group (n = 35)
C (− ++ −) 18 (51) 30
D (− − − −) 17 (49) 32
Total 57 (100)
*I, II, III, and IV represent the 4 blood sampling points in each patient, as
described in the text.
Results
CEA mRNA expression in blood before, during, and
after VATS. The CEA mRNA expression pattern in the
peripheral blood samples before, during, and after
operation for the 32 patients with NSCLC who had
undergone VATS lobectomy as it relates to pathologic
TNM stage is summarized in Table I. The blood sam-
ples of both patients with stage IIIA NSCLC were con-
sistently positive (ie, positive at all sampling points).
The blood samples of 1 patient with stage IIA disease
(carcinoid) were consistently negative at all sampling
points. When we analyzed CEA mRNA expression pat-
tern in patients with stage IA or IB disease, the preop-
erative blood samples from 11 of 29 patients (38%)
were positive for CEA mRNA. Of these 11 patients, 5
patients (45%) showed consistently positive CEA
mRNA during and after operation (ie, positive at all
sampling points), although the remaining 6 patients
(55%) were found to have negative samples during and
after the operation (ie, at sampling points III-VI or II-
VI). On the other hand, in 18 patients with preoperative
negative CEA mRNA blood samples, 16 patients (89%)
had detectable CEA mRNA in peripheral blood during
or after operation (ie, positive at points II and III, II, III,
V and VI, or II, III, and VI), although samples from the
remaining 2 patients (11%) were consistently negative
at all sampling points.
We compared the occurrence of each CEA mRNA
expression pattern in 29 patients with stage IA and IB
NSCLC who underwent VATS lobectomy in this study
to 57 patients who underwent open lobectomy and
whose blood samples were assayed for CEA mRNA by
RT-PCR at sampling points I, II, III, and IV in our pre-
vious study.11 The treatment groups were comparable in
terms of baseline characteristics, such as age, gender,
smoking history, and histologic type (data not shown).
Table II shows the summary of CEA mRNA expression
patterns in the 57 patients with stages IA or IB NSCLC.
Those are pattern A (persistently positive for CEA
mRNA at all sampling points; positive at points I-IV),
pattern B (preoperative positive CEA mRNA, which
was negative during the operation; positive only at sam-
pling points I and II or I), pattern C (before the opera-
tion, negative for CEA mRNA but positive when sam-
pled during the operation; positive only at points II and
III), and pattern D (consistently negative for CEA
mRNA; negative at all 4 sampling points).
In the present VATS group, the preoperative blood
samples from 11 of 29 patients (38%) with stage I
NSCLC were positive for CEA mRNA, which is
almost the same occurrence in the 57 patients in our
previous study (22/57 patients; 39%). Of these 11
patients, 5 patients (45%) showed consistently posi-
tive CEA mRNA during and after operation, although
the remaining 6 patients (55%) were negative for
CEA mRNA during the operation and remained nega-
tive after the operation. The occurrence of patients
with a consistently positive pattern during the opera-
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Fig 1. Disease-free and overall survival in 57 patients with NSCLC who underwent conventional open lobectomy
in terms of pathologic TNM stage during operation.
tion tended to be higher in the present VATS lobecto-
my group (5/11 patients; 45%) than in the open lobec-
tomy group (6/22 patients; 27%; P = .09). However,
when compared with patients with initially negative
samples for CEA mRNA, 16 of 18 patients (89%)
with initially negative CEA mRNA blood samples
were positive for CEA mRNA during operation (ie,
positive at sampling points II and III in the present
study). The occurrence of this change (89%) was sig-
nificantly higher than that in the open lobectomy
study (18/35 patients; 51%; P < .001).
Prognostic analysis of CEA mRNA expression
pattern in patients with NSCLC who underwent
open lobectomy. To examine whether the CEA mRNA
expression pattern in the peripheral blood during oper-
ation is associated with the prognosis of patients with
NSCLC, we analyzed the prognostic value of CEA
mRNA expression pattern in the 57 patients with stage
IA or IB NSCLC whose blood samples were previous-
ly assayed for CEA mRNA by RT-PCR at sampling
points I, II, III, and IV.
Fig 1 shows disease-free and overall survival curves
that are stratified by pathologic TNM stage in the
peripheral blood during the operation. There is no sta-
tistical difference in disease-free and overall survival
between patients with stage IA and stage IB NSCLC.
However, when the patient prognosis was analyzed in
terms of CEA mRNA expression pattern in the periph-
eral blood during the operation, patients with pattern A
(ie, positive at all 4 sampling points) had a significant-
ly shorter disease-free and overall survival when com-
pared with those patients with the other 3 patterns for
CEA mRNA expression during operation (Fig 2). With
respect to overall survival, patients with pattern C (ie,
positive only at sampling points II and III) are likely to
have a poorer prognosis when compared with those
patients with patterns B (positive before operation
only) and D (negative at all sampling points). However,
there was no statistical difference in overall survival
between patterns C and B and patterns C and D.
Discussion
Current imaging techniques allow the operating sur-
geon to see only the visceral and parietal pleural sur-
faces of the thoracic cavity, with palpation of tissues
limited to what can be reached by fingertips inserted
between ribs. This limitation of VATS procedure raises
concerns that VATS techniques may be more likely to
disseminate malignant tumors than the type of manip-
ulation that occurs during an open thoracotomy.
Pulling the tumor mass by instruments through rela-
tively small incisions may disrupt the tumor. It may
even be possible that the assisting surgeon may acci-
dentally grasp the tumor directly. It is also possible that
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Fig 2. Disease-free and overall survival in 57 patients with NSCLC who underwent conventional open lobectomy
in terms of CEA mRNA expression pattern during surgery. At sampling points I through IV: Pattern A, + + + +;
Pattern B, + + − − or + − − −; Pattern C, – + + –; Pattern D, − − − −.
hematogenous cancer cell dissemination could result
from frequent attempts to pull the pulmonary lobe con-
taining the tumor from all sides by forceps to get a bet-
ter field of vision and to ligate the lobar bronchovascu-
lar pedicles through a small chest incision. All these
technical limitations of VATS do not allow surgeons to
perform a “gentle handling” of the malignant tumor as
compared with the standard open surgery.
In the present study, we have determined the percent-
age of patients with resectable NSCLC who underwent
VATS lobectomy and who have detectable levels of
tumor cells in their circulation before, during, and after
operation; RT-PCR was used to detect CEA mRNA. We
have compared the occurrence of CEA-expressing cells
to that of patients with NSCLC who had undergone
open lobectomy in our previous study.11 A surprising
difference in the CEA mRNA expression pattern
between the present VATS lobectomy group and the
previously studied open lobectomy group was observed
in patients who tested negative for CEA mRNA before
operation. In 18 patients with stage I NSCLC with ini-
tially negative CEA mRNA blood samples in the pres-
ent study, 16 patients (89%) had detectable CEA
mRNA in the circulation during the operation. The
occurrence of this change (89%) was significantly
higher than that in the open lobectomy study (18/35
patients; 51%).
It is not clear why the rate of intraoperative positive
CEA mRNA was higher in the initially negative group
than in the initially positive group. One possible expla-
nation is that sampling errors may be occurred. In this
study, we performed single-point blood sampling.
However, because cancer cells may be shed intermit-
tently into the bloodstream,18 patients who have nega-
tive blood results might have circulating tumor cells
intermittently at another time or under other circum-
stances. Future study is necessary regarding whether
sampling errors occur when only single-point blood
samples are taken.
Although the number of patients is small, there were 4
patients whose CEA mRNA expression pattern was ini-
tially negative, was detectable during but not immediate-
ly after the operation, and then was positive again sever-
al weeks after the operation (points V and/or VI). The
meaning of this finding is unclear. It is generally
believed that most of the cancer cells shed into the
bloodstream of the tumor will be destroyed ultimately by
natural defense mechanisms and that very few tumor
cells succeed in establishing secondary tumors.19
However, a possible explanation for our finding is that
some tumor cells that were shed into the bloodstream by
the surgical manipulation may survive in a selected sub-
set of patients. These could succeed in establishing sec-
ondary tumors, which could in turn shed tumor cells into
the bloodstream at some interval after the operation.
To date, it is not clear whether the technical problems
of VATS lobectomy will lead to an increased risk of
recurrence or metastasis. In 57 patients with stage I
NSCLC, although they had undergone open lobectomy
but not VATS lobectomy, patients who have persistent-
ly positive blood samples during operation showed sig-
nificantly worse prognoses than any other expression
patterns for CEA mRNA. Thus patients who have per-
sistently positive blood samples during operation may
be considered at highest risk for systemic relapse.
However, it remains unclear (in patients with NSCLC
who have undergone VATS lobectomy) whether
patients who have persistent evidence of circulating
tumor cells by RT-PCR for CEA mRNA or who have
detectable CEA mRNA both during and several weeks
after the operation show worse prognoses than those
patients with no evidence of circulating tumor cells a
few weeks after the procedure.
We realize that the participants in this study have had
less experience with the VATS lobectomy procedure
compared with their extensive experience with open
lobectomy. Lewis,20,21 McKenna,22 and their associates
reported a larger series of VATS lobectomies for lung
cancer with favorable prognoses. There may be possi-
ble differences related to learning curve issues and
more manipulation in the early going in our hands ver-
sus more experienced investigators. Therefore it may
be too early to try to draw definite conclusions.
However, our findings should alert surgeons, at least at
this time and at least for inexpert surgeons, to the pos-
sible danger of tumor dissemination during a VATS
lobectomy for NSCLC and suggest that this type of
operation has the potential to adversely influence long-
term survival of patients with NSCLC. The long-term
follow-up of our patient cohort will provide data on the
prognostic relevance of circulating tumor cells and will
also answer the important question of whether the tech-
nical problems of VATS lobectomy will actually lead to
an increased risk of systemic disease as compared with
open lobectomy.
The long-term control of disease, particularly malig-
nant disease, is of far more importance to the patient
than short-term goals such as pain control and length of
hospital stay.23-25 In many institutions, insufficient time
has elapsed to report on the 5-year survival of patients
with NSCLC after VATS lobectomy, the ultimate crite-
rion in the management of lung cancer. The potential
short-term benefit or the surgeon’s ability to perform a
VATS procedure is of little value to the patients with
lung cancer if the goal of long-term survival is com-
promised. Before the widespread adoption of VATS
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procedures for the curative resection of lung cancer,
future long-term follow-up studies are needed.
We thank Jill M. Siegfried for a critical reading of the man-
uscript.
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